Covington Guides Selecta Biosciences Through Merger With Cartesian Therapeutics, Concurrent Private Placement
November 13, 2023
November 13, 2023
NEW YORK, Nov. 13 -- Covington, a law firm, issued the following news release:
Covington represented Selecta Biosciences, a public clinical-stage biotechnology company, in its merger with Cartesian Therapeutics and concurrent $60.25 million private investment in public equity (PIPE).
As a result of the merger and PIPE, the combined company expects to have over $110 million on hand to support the development of Cartesian's leading product candidate Descartes-08, a potent . . .
Covington represented Selecta Biosciences, a public clinical-stage biotechnology company, in its merger with Cartesian Therapeutics and concurrent $60.25 million private investment in public equity (PIPE).
As a result of the merger and PIPE, the combined company expects to have over $110 million on hand to support the development of Cartesian's leading product candidate Descartes-08, a potent . . .